Caris Life Sciences, Inc. (CAI) AI Stock Analysis

Caris Life Sciences, Inc. is an artificial intelligence TechBio company providing molecular profiling services in the United States and internationally. It develops and commercializes solutions using molecular information and artificial intelligence or machine learning algorithms to transform healthcare. Its portfolio includes the MI Profile Platform for tissue-based profiling, Caris Assure Platform for blood-based profiling, Precision Whole Genome Platform, Caris Detect for multi-cancer early detection, Caris WGS MRD for minimal residual disease detection, and Caris ChromoSeq for hematological cancers. It also delivers laboratory, strategic data, and research services to biopharmaceutical customers, serving hospitals, institutions, and patients.

Annual revenue grew from $294.0M in FY2020 to $812.0M in FY2025, representing a 5-year compound annual growth rate of 14.3% from FY2019 to FY2025. In FY2025, revenue grew 97.0%, while gross margin rose to 66.4% from 43.4% in FY2024. Operating margin turned positive at 5.6% in FY2025 following operating margins of -122.2% in FY2022, -104.4% in FY2023, and -62.4% in FY2024. Net income in FY2025 stood at -$538.0M with diluted EPS of -$1.10. Over the trailing twelve months ended June 30, 2026, revenue totaled $989.6M with a profit margin of 10.6%, an operating margin of 10.2%, and EPS of $1.69.

As of June 30, 2026, Caris Life Sciences held $793.1M in cash and short-term investments against total debt of $452.4M, resulting in net cash of $340.7M. Total assets stood at $1.23B and shareholders' equity was $591.7M, yielding a current ratio of 5.53 and a debt-to-equity ratio of 0.76. In FY2025, the company generated $83.2M in operating cash flow and $66.9M in free cash flow, deploying $16.3M to capital expenditures and $113,000 to share buybacks.

At a share price of $30.56, Caris Life Sciences carries a market capitalization of $8.64B and an enterprise value of $8.60B. The stock trades at a trailing price-to-earnings multiple of 18.1x, below the 24.6x median of its US-listed Healthcare peers. Its forward price-to-earnings multiple of 43.3x trades at a premium to the peer median of 17.3x, while its price-to-sales of 8.7x compares to 4.1x for peers. Over the past year, the stock returned -4.4%, underperforming the 16.8% return of the S&P 500 (SPY).

Wall Street analysts cover Caris Life Sciences with 9 Strong Buy, 1 Buy, and 4 Hold ratings, with no Sell or Strong Sell ratings. The mean price target is $31.62, representing a 3.5% upside over the last close of $30.56. For the fiscal year ending December 31, 2026, consensus estimates project revenue of $1.03B and EPS of $0.14. For the following fiscal year, 11 analysts project revenue of $1.23B and EPS of $0.37. The company has beat EPS estimates in 3 of the last 4 quarters, with the next earnings date set for November 4, 2026.

This page is an AI-written research summary of Caris Life Sciences, Inc. (CAI). The text was generated on October 30, 2026 from Quotelinks data as of October 16, 2026 (company profile, annual results, latest balance sheet, valuation, price performance and analyst estimates). An automatic check rejects any draft that contains a figure not found in that data. It is not investment advice; verify figures on the linked tabs before making decisions.

Related: CAI income statement, CAI balance sheet, CAI key metrics, CAI analyst forecast, CAI chart. See the CAI stock overview for the latest quote and news.